Pocket watch found on Titanic victim to go on sale in UK
A pocket watch, tickets and money found among the belongings of passengers on the Titanic are among items on sale at a UK auction later this month.
The gilt silver and brass watch was found among the possessions of Danish second-class passenger Hans Christensen Givard, who was among the 1,500 people who died when the vessel sank after hitting an iceberg in 1912.
His body was recovered from the North Atlantic and buried in Halifax, Canada, on 10 May 1912.
Givard's pockets contained a savings book, keys, cash in a wallet, a compass, a passport and the gilded pocket watch, which it is estimated will fetch around £50,000 ($66,000) at the April 26 auction.
The belongings were returned to his family and his descendants are now selling the watch.
Givard, 27, was travelling to the United States with two of his friends who also died in the disaster.
"The watch's movement is frozen in time at the moment the cold North Atlantic waters consumed not only its owner but the most famous ocean liner of all time, Titanic, on April 15, 1912," said Andrew Aldridge, of Henry Aldridge and Son auctioneers.
Other items on sale include a letter and medal belonging to first-class Swedish passenger Erik Gustaf Lind and a silver dollar certificate and rare third-class ticket used by Ernest Portage Tomlin.
Both men died in the disaster.
The violin played by the bandleader in the 1997 Hollywood film depicting the sinking is also on sale, and is expected to fetch up to £60,000.
jwp/jkb/rlp
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
Zara owner Inditex flags slowing summer sales as quarterly revenues miss expectations
Zara owner Inditex on Wednesday posted weaker-than-expected quarterly sales while flagging a slower start to the summer season than last year amid broader economic uncertainty. The Spanish retailer reported revenues of 8.27 billion euros ($9.44 billion) in the fiscal first quarter covering Feb. 1 to April 30, slightly shy of the 8.39 billion euros forecast by LSEG analysts. Net income came in at 1.3 billion euros for the quarter, compared to the 1.32 billion euros analysts estimated. The company also reported a slower start to summer sales, which increased 6% at constant currencies from May 1 to June 9 versus 12% growth in the same period last year on a constant currency basis. Back in March, Inditex flagged a slowdown in demand at the start of the year, which CEO Óscar García Maceiras at the time attributed to uncertainty around U.S. tariffs. Shares plunged on the comments and the stock currently remains down around 12% from its Dec. 4 peak, as of Monday. The comments came as Inditex sales rose annually in the fourth quarter to 11.21 billion, meeting expectations. It followed a rare miss on sales and profit in the third quarter as flooding in Spain impacted consumer spending. The company, which also owns a series of high street brands including Pull & Bear, Bershka and Massimo Dutti, is often seen as a barometer for broader consumer sentiment. It has also been etching out a clear lead on high street rival H&M, which posted weaker-than-expected fiscal first quarter revenues in March, as sales continue to soften at the Swedish fashion giant. The two retail giants have nevertheless struggled with increased competition from lower-cost fast fashion brands such as Chinese-founded Shein and Temu.
Cosmopolitan
2 hours ago
- Cosmopolitan
The tragic true story of Titan: The OceanGate Disaster and the submersible implosion
On 18 June 2023, five passengers descended into the Atlantic Ocean in the hopes of seeing the famed wreckage of the doomed Titanic. They would have been prepared to see something incredible from the viewpoint of the Titan, the submersible they were travelling in. Instead, the ship's carbon fibre was struggling to uphold against the ocean's enormous pressure, and Titan imploded at supersonic speeds. All five passengers on board were instantly killed. A four-day search and rescue mission took place, with the remainder of what was left of the Titan found on the ocean floor, shredded. Netflix's latest series, Titan: The OceanGate Disaster now looks to explore this tragedy in granular detail, focusing on billionaire Stockton Rush – the man behind the submersible, who also perished onboard his own creation. Here's everything you need to know. The new Netflix documentary looks at the rise of OceanGate, an American company that wanted to launch deep sea tourism. Founded by Stockton Rush and Guillermo Söhnlein in 2009, the company built two submersible vessels – one of which being the infamous Titan. Söhnlein left the company in 2013. Rush, meanwhile, was the charismatic face of the brand. 'There's a huge demand for unique travel experiences,' he said in 2017. 'We will be profitable from the Titanic trips.' Born into a wealthy family, Rush was an American businessman with a taste for adventure. He started scuba diving aged 12 and acquired a pilot's licence when he was 18. He initially thought about being an air force pilot, but was rejected for his eyesight not being good enough. In 2006, after he went on his first submarine excursion, Rush began to toy with the idea of deep sea travel, and hoped to tap into the growing demand for adventure tourism. He wanted to build submersibles that went far deeper under the sea than other commercial submersibles. Speaking to The Independent in 2017, Rush explained: 'Shallow dives equal shallow experience. The commercial subs out there are like a Disneyland ride versus paddling yourself through the Grand Canyon. Knowing you're there changes how you observe it.' Understandably, there are strict regulations for submersible travel, which Rush previously criticised. He once decried the Passenger Vessel Safety Act of 1993 as 'needlessly prioritis[ing] passenger safety over commercial innovation'. Rush also spoke passionately about the 'move fast and break things' culture typically attributed to start-ups. At the 2022 GeekWire summit, he told audiences: 'If you're not breaking things, you're not innovating. If you're operating within a known environment, as most submersible manufacturers do, they don't break things. To me, the more stuff you've broken, the more innovative you've been.' Speaking of his former co-founder, Guillermo Söhnlein told Vanity Fair: 'I think [Rush] did see himself in the same vein as these disruptive innovators. Like Thomas Edison, or any of these guys who just found a way of pushing humanity forward for the good of humanity — not necessarily for himself. He didn't need the money. He certainly didn't need to work and spend hundreds of hours on OceanGate. You know, he was doing this to help humanity. At least that's what I think was personally driving him.' The deep-sea vessel, built by OceanGate, was to focus on diving as far as 3,800 meters below sea level to visit the wreckage of the Titanic. What made it different to other submersibles, usually comprised of titanium or steel in order to withstand the extreme levels of external pressure that are attributed to deep-sea diving, was that the Titan had a filament-wound carbon fibre hull. This material made the submersible lighter and more cost effective – but was not as reliable and could fail when too much pressure was applied. Rush was told this by numerous employees and experts in the field, who warned of potential 'catastrophic' issues, but nothing was done to amend the submersible. Titan was also not 'classed', which meant that it did not undergo formal safety inspections or meet the standards of established classification societies. In 2019, OceanGate explained why this was the case. In a press release, the company said: 'Bringing an outside entity up to speed on every innovation before it is put into real-world testing is anathema to rapid innovation.' The submersible was also controlled by a modified video game controller, with the 'pilot' receiving instructions from the surface vessel above through a text-based messaging system. No real training was required before getting on board, with any training needed to take part being provided online. However, those who paid for their seat on the submersible (a princely sum of up to $250,000, or £195,000), were expected to sign a detailed waiver that said that going on the Titan could 'result in physical injury, disability, emotional trauma or death'. Despite numerous warnings, Titan launched in 2021 with its first dive to the Titanic's wreckage. Between 2021 and 2022, the submersible made 23 dives, with 13 of these managing to reach the wreckage. On its final outing, the Titan was just 1600m away from the bow of the Titanic. Onboard the Titan's final voyage on 18 June were: Stockton Rush – 61 – OceanGate CEO Paul-Henri Nargeolet – 77 – deep sea explorer and Titanic expert Hamish Harding – 58 – businessman Shahzada Dawood – 48 – businessman Suleman Dawood – 19 – university student and Dawood's son Originally Christine Dawood was meant to be going on the dive. However, she reportedly gave up her seat for her son, because he expressed an interest in going on the trip. He reportedly took a Rubik's cube on Titan, as he hoped he would be able to break a world record while seeing the wreckage. Rear Admiral John Mauger explained in a press conference after the Titan was found that the wreckage was consistent with a 'catastrophic loss of the pressure chamber.' Effectively, the carbon fibre material could not withstand the external pressure of a deep sea dive. When the submersible did not reemerge at its scheduled time, the US coast guard was notified. Titan only had 96 hours of breathable air supply for its five passengers when it set out, which added a time pressure to finding those onboard. Four days later, on 22 June, debris from the Titan submersible was found by the US coast guard, near the Titanic's wreckage. All planned excursions by the company were immediately cancelled, with its main office closed the day the Titan wreckage was found. On 6 July, all business operations were suspended, with OceanGate now only serving as a legal entity. The family of French explorer Paul-Henri Nargeolet filed a $50 million wrongful death lawsuit against OceanGate in August 2024. The US Coast Guard launched an investigation, which also led to a public hearing in September 2024. During this time, former employees testified saying they warned of the submersible's safety. US court documents show OceanGate's former operations director David Lochridge had significant concerns with the Titan's design, including that it was made from carbon fibre which he warned would damage further with every dive. Titan: The OceanGate Disaster is available to watch on Netflix now Kimberley Bond is a Multiplatform Writer for Harper's Bazaar, focusing on the arts, culture, careers and lifestyle. She previously worked as a Features Writer for Cosmopolitan UK, and has bylines at The Telegraph, The Independent and British Vogue among countless others.
Yahoo
3 hours ago
- Yahoo
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech ABSalipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong PharmaceuticalDaewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd.
